We produced a new ADC system using anti-GPC-1 monoclonal antibody and monomethyl auristatin F (MMAF), and demonstrated its potential effectiveness against uterine cervical cancer.23 The aims of this study were to investigate the GPC-1 expression in pancreatic cancer, and assess the feasibility of applying GPC-1-ADC as a new drug delivery technology. The gene discussed is GPC1; the disease is pancreatic neoplasm.